PIPELINE Actelion’s pipeline has made significant progress, with macitentan (Opsumit) entering into III for the treatment of children with PAH, and the advancement of the new dual orexin receptor antagonist into Phase II development for the treatment of insomnia. In addition, inclusion of participants in the ongoing Phase III studies for cadazolid and ponesimod is progressing well and is on target to be completed by the end of 2016. The MERIT study of macitentan for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) has completed enrollment and is on schedule to deliver results by the end of the year. Compound Indication Study Status Clostridium difficile-associated Cadazolid IMPACT Ongoing diarrhea Macitentan Eisenmenger syndrome MAESTRO Ongoing Phase III Pediatric PAH TOMORROW Initiating Macitentan Ponesimod Multiple sclerosis OPTIMUM Ongoing Cenerimod Systemic lupus erythematosus - Ongoing Reversal of vasospasm associated Clazosentan with aneurysmal subarachnoid REVERSE Ongoing hemorrhage Dual Orexin Receptor Insomnia - Initiating Antagonist Endothelin Phase II Receptor Specialty cardiovascular disorders - Ongoing Antagonist Chronic thromboembolic pulmonary Macitentan MERIT Ongoing hypertension Combined pre- and post-capillary Macitentan MELODY Complete pulmonary hypertension Ponesimod Graft-versus-host disease - Ongoing Phase Ib Lucerastat Fabry disease - Complete New Chemical Cardiovascular disorders - Ongoing Entity Selective Orexin 1 Receptor Neurological disorders - Ongoing Antagonist Phase I T-type Calcium Neurological disorders - Ongoing Channel Blocker RESULTS DAY CENTER Investor community: To make your job easier, we provide links to all relevant documentation, such as a full financial review, reconciliation US-GAAP to Core results and geographical breakdown by product, from the Results Day Center on our corporate website: www.actelion.com/results-day-center.
PIPELINE Actelion’s pipeline has made significant progress, with macitentan (Opsumit) entering into III for the treatment of children with PAH, and the advancement of the new dual orexin receptor antagonist into Phase II development for the treatment of insomnia. In addition, inclusion of participants in the ongoing Phase III studies for cadazolid and ponesimod is progressing well and is on target to be completed by the end of 2016. The MERIT study of macitentan for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) has completed enrollment and is on schedule to deliver results by the end of the year. Compound Indication Study Status Phase III Cadazolid Clostridium difficile-associated diarrhea IMPACT Ongoing Macitentan Eisenmenger syndrome MAESTRO Ongoing Macitentan Pediatric PAH TOMORROW Initiating Ponesimod Multiple sclerosis OPTIMUM Ongoing Phase II Cenerimod Systemic lupus erythematosus - Ongoing Clazosentan Reversal of vasospasm associated with aneurysmal subarachnoid hemorrhage REVERSE Ongoing Dual Orexin Receptor Antagonist Insomnia - Initiating Endothelin Receptor Antagonist Specialty cardiovascular disorders - Ongoing Macitentan Chronic thromboembolic pulmonary hypertension MERIT Ongoing Macitentan Combined pre- and post-capillary pulmonary hypertension MELODY Complete Ponesimod Graft-versus-host disease - Ongoing Phase Ib Lucerastat Fabry disease - Complete New Chemical Entity Cardiovascular disorders - Ongoing Phase I Selective Orexin 1 Receptor Antagonist Neurological disorders - Ongoing T-type Calcium Channel Blocker Neurological disorders - Ongoing RESULTS DAY CENTER Investor community: To make your job easier, we provide links to all relevant documentation, such as a full financial review, reconciliation US-GAAP to Core results and geographical breakdown by product, from the Results Day Center on our corporate website: www.actelion.com/results-day-center.